Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozerem for delirium prevention in hospitalized older adults
NCT03165695Phase 4Withdrawn
- Sponsor
- Brigham and Women's Hospital
- Start
- Dec 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ramelteon in delirium, sponsored by Brigham and Women's Hospital. Primary endpoint: Incidence of delirium at 7 days. Planned start Dec 2019; status: withdrawn.
02
Drugs
ramelteon
03
Conditions
delirium
Beyond the preview
Go deeper on NCT03165695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03165695.